Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 Trial of APX-343A as Monotherapy or in Combination With Pembrolizumab to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy in Subjects With Advanced Solid Tumors

NCT07123415 is registered in ClinicalTrials.gov with Aptabio Therapeutics, Inc. as lead sponsor.

NCT NCT07123415
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07123415 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 Trial of APX-343A as Monotherapy or in Combination With Pembrolizumab to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy in Subjects With Advanced Solid Tumors
Lead sponsor
Aptabio Therapeutics, Inc.
Phase
Phase 1
Overall status
Recruiting
Start date
October 24, 2025
Completion date
December 31, 2028
Enrollment
110 (estimated)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

advanced solid cancer, advanced solid tumor (phase 1)